Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 21:15:1371559.
doi: 10.3389/fimmu.2024.1371559. eCollection 2024.

Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy

Junlei Hou #  1   2 , Xuezhi Yang #  1   2 , Shuanglong Xie #  1   2 , Bo Zhu  1   2 , Haoran Zha  3
Affiliations
Review

Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy

Junlei Hou et al. Front Immunol. .

Abstract

Anti-PD-(L)1 therapy has shown great efficacy in some patients with cancer. However, a significant proportion of patients with cancer do not respond to it. Another unmet clinical need for anti-PD-(L)1 therapy is the dynamic monitoring of treatment effects. Therefore, identifying biomarkers that can stratify potential responders before PD-(L)1 treatment and timely monitoring of the efficacy of PD-(L)1 treatment are crucial in the clinical setting. The identification of biomarkers by liquid biopsy has attracted considerable attention. Among the identified biomarkers, circulating T cells are one of the most promising because of their indispensable contribution to anti-PD-(L)1 therapy. The present review aimed to thoroughly explore the potential of circulating T cells as biomarkers of anti-PD-(L)1 therapy and its advantages and limitations.

Keywords: CD4+ T cell; CD8+ T lymphocyte subsets; anti-PD-(L)1 therapy; biomarker; circulating T cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision

Figures

Figure 1
Figure 1
Prognostic value of circulating T cell subsets in the context of PD-(L)1 efficacy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. . Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. (2018) 9:5361. doi: 10.1038/s41467-018-07767-w - DOI - PMC - PubMed
    1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New Engl J Med. (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Song R, Liu F, Ping Y, Zhang Y, Wang L. Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction. biomark Res. (2023) 11:57. doi: 10.1186/s40364-023-00498-1 - DOI - PMC - PubMed
    1. Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol Off J Eur Soc Med Oncol. (2019) 30:1448–59. doi: 10.1093/annonc/mdz196 - DOI - PubMed
    1. Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. . Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. (2019) 25:1251–9. doi: 10.1038/s41591-019-0522-3 - DOI - PMC - PubMed

Publication types

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Nature Science Foundation of China (No. 82272808 to HZ, No. 82230095 to BZ).